PT  - JOURNAL ARTICLE
AU  - Testa, Sophie
AU  - Palareti, Gualtiero
AU  - Legnani, Cristina
AU  - Dellanoce, Claudia
AU  - Cini, Michela
AU  - Paoletti, Oriana
AU  - Ciampa, Antonio
AU  - Antonucci, Emilia
AU  - Poli, Daniela
AU  - Morandini, Rossella
AU  - Tala, Maurizio
AU  - Chiarugi, Paolo
AU  - Santoro, Rita Carlotta
AU  - Iannone, Angela Maria
AU  - Candia, Erica De
AU  - Pignatelli, Pasquale
AU  - Faioni, Elena Maria
AU  - Chistolini, Antonio
AU  - Esteban, Maria del Pilar
AU  - Marietta, Marco
AU  - Tripodi, Armando
AU  - Tosetto, Alberto
AU - MAS Study group
TI  - LOW LEVELS OF DIRECT ORAL ANTICOAGULANTS AT STEADY STATE IN ATRIAL FIBRILLATION PATIENTS WHO LATER DEVELOP THROMBOTIC COMPLICATIONS; THE PROSPECTIVE MAS (MEASURE AND SEE) STUDY
AID  - 10.1101/2023.12.08.23299746
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.08.23299746
4099  - http://medrxiv.org/content/early/2023/12/10/2023.12.08.23299746.short
4100  - http://medrxiv.org/content/early/2023/12/10/2023.12.08.23299746.full
AB  - Background Though effective and safe, treatment with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) is still associated with thrombotic complications. Whether the measurement of DOAC levels may improve the efficacy of treatment is an open issue.Methods We carried out the observational, prospective, multicenter study [“Measure and See” Study (MAS) (NCT03803579)]. Blood was collected 15-30 days after starting DOAC treatment in AF patients, who were then followed for one year. Plasma samples were centralized, for DOAC levels measurement. Patients’ DOAC levels were converted into drug/dosage standardized values to allow a pooled analysis in a time-dependent, competitive-risk model. The measured values were transformed into standardized values by subtracting from the original values the overall mean value of each DOAC and divided by the standard deviation. Standardized values represent the distance of each value from the overall mean.Results Trough and peak DOAC levels were assessed in 1657 and 1303 patients, respectively. Twenty-one thrombotic complications were recorded during 1606 years of follow-up (incidence of 1.31% patient/years). 17/21 thrombotic events occurred in patients whose standardized activity levels were below the mean of each DOAC (zero); the incidence was the highest (4.08% patient/years) in patients whose standardized values were in the lowest class (below zero, σ; - 1.00).Conclusions Early measurement of DOAC levels in AF patients allowed us to identify most of the subjects who, having low baseline DOAC levels, subsequently developed thrombotic complications. Further studies are warranted to assess whether thrombotic complications may be reduced by measuring baseline DOAC levels and modifying treatment when indicated.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03803579Funding StatementThe study was promoted and funded by the ?Arianna Anticoagulazione? Foundation, which has received an unrestricted grant from the Fondazione ?Cassa di Risparmio in Bologna? to support the study. Becton-Dickinson (Franklin Lakes, NJ, USA) provided test tubes for blood sampling, and Diagnostica Stago (Asnieres-sur-Seine, France) provided reagents to perform DOAC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Independent review board approval was obtained before all study-related activity from the Ethics Committee (EC) of the coordination center (Cremona) (approval number 14725; 02/05/2018) and from the ECs of all other centers. Written informed consent was obtained from each patient before enrolment. The study promoter provided measures to safeguard the subject's privacy and the protection of personal data according to the EU GDPR 2016/679 and Italian law.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesFor original data, please contact c.legnani{at}fondazionearianna.org